Drug Trial Radar · NCT05612581
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
May 10, 2023
Primary completion
Oct 15, 2024
Study completion Aug 19, 2025
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 66 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
Conditions
- Hepatitis B, Chronic
Interventions
VIR-3434Drug
VIR-3434 given by subcutaneous injection
VIR-2218Drug
VIR-2218 given by subcutaneous injection
TDFDrug
TDF given orally
PEG-IFNαDrug
PEG-IFNα given by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of TreatmentTime frame: Up to 48 weeks
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
Investigative Site
Clichy, France
Investigative Site
Nice, France
Investigative Site
Rennes, France
Investigative Site
Toulouse, France
Investigative Site
Hong Kong, Hong Kong
Investigative Site
Hong Kong, Sha Tin, Hong Kong
Investigative Site
Chisinau, Moldova
Investigative Site
Bucharest, Romania
Investigative Site
Busan, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Yangsan, South Korea
Investigative Site
Glasgow, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.